

General information about company	
Name of The Company	SANDU PHARMACEUTICALS LIMITED
BSE Scrip Code	524703
NSE Symbol	
MSE Symbol	
Date of Start of Financial Year	01-04-2022
Date of End of Financial Year	31-03-2023
Reporting Period	Second half yearly
Date of Start of Reporting Period	01-10-2022
Date of End of Reporting Period	31-03-2023
Level of rounding to be used in disclosing related party transactions	Lakhs
Whether the company has any related party?	Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?	Yes

(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public	NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of bank's staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure.	NA
(III) Whether the company is a 'high value debt listed entity' according to regulation 15 (1A)?	No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?	
(b) If answer to above question is No, please explain the reason for not complying.	

Related party transactions														Additional disclosure of related party transactions relates to loans, inter-corporate deposits, as entity/subsidiary. These details need to be disclosed			
Sr No.	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments				Details (Nature of advance/intercorp deposit/investment)
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary						Opening balance	Closing balance	Nature of indebtedness (loan/issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	
1	M/s Sandu Pharmaceuticals Ltd.	AAACS6291G	M/s Sandu Brothers Pvt. Ltd	AADCS9226L	Entities in which KMP are Interested	Purchase of goods or services		Approved by Audit committee/Board /Shareholders	1120.63	0	0						
2	M/s Sandu Pharmaceuticals Ltd.	AAACS6291G	M/s Sandu Brothers Pvt. Ltd	AADCS9226L	Entities in which KMP are Interested	Sale of goods or services		Approved by Audit committee/Board /Shareholders	0	0	0						
3	M/s Sandu Pharmaceuticals Ltd.	AAACS6291G	Mr. Umesh Bhaskar Sandu	ABWPS9336G	Entities in which KMP are Interested	Remuneration		NA	42.25	0	0						
4	M/s Sandu Pharmaceuticals Ltd.	AAACS6291G	M/s Sandu Brothers Pvt. Ltd	AADCS9226L	Entities in which KMP are Interested	Any other transaction	royalty paid	Approved by Audit committee/Board /Shareholders	63.4	0	0						
5	M/s Sandu Pharmaceuticals Ltd.	AAACS6291G	Rakesh Parekh	AMYPP0706G	Key management personnel of entity or parent	Remuneration		NA	14.38	0	0						
6	M/s Sandu Pharmaceuticals Ltd.	AAACS6291G	Pratika Mhambrey	CTQPS2943K	Key management personnel of entity or parent	Remuneration		NA	6.27	0	0						
7	M/s Sandu Pharmaceuticals Ltd.	AAACS6291G	M/s Sandu Brothers Pvt. Ltd	AADCS9226L	Entities in which KMP are Interested	Any other transaction	Outstanding details	NA	296.95	0	0						
Total value of transaction during the reporting period									1543.88								

